by The global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market is estimated to be valued at US$ 3,071.1 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Cancer chemotherapy associated nausea and vomiting therapeutics are drugs that help reduce nausea and vomiting as side effects of chemotherapy for cancer treatment. These drugs act on various receptors in the brain to block signals that trigger feelings of nausea and vomiting.
Market key trends:
One of the key trends in the cancer chemotherapy associated nausea and vomiting therapeutics market is the growing focus on development of new drugs with novel mechanisms of action for refractory nausea and vomiting. Currently available drugs such as 5-HT3 receptor antagonists and NK1 receptor antagonists are ineffective in around 30% of patients receiving highly emetogenic chemotherapy. Hence, companies are engaged in developing new antiemetics that target other receptor pathways and neuropeptides associated with vomiting center of brain like netupitant palonosetron fixed combination and other NK1 receptor antagonists with substance P inhibition. Additionally, cannabinoid receptor type 1 antagonists are also under development for chemotherapy induced nausea and vomiting. One of the key trends in cancer chemotherapy associated nausea and vomiting therapeutics market is the rising adoption of combination therapies. There has been a shift from single drug therapies to combinations of different classes of anti-emetic drugs like 5-HT3 receptor antagonists, NK1 receptor antagonists and corticosteroids. Combination therapies have significantly higher complete response rates compared to single drug therapies and are recommended as the standard of care in cancer chemotherapy associated nausea and vomiting guidelines.
SWOT Analysis
Strength: Growing prevalence of cancer and increasing focus on developing novel and safer anti-emetic therapies.
Weakness: High development costs associated with drug development and stringent regulatory approvals.
Opportunity: Rising healthcare expenditure in emerging markets and untapped potential in low/middle income countries.
Threats: Patent expiries of blockbuster drugs and intense competition from generic manufacturers.
Key Takeaways
The Global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing prevalence of cancer cases globally.
Regional analysis: North America dominated the market in 2023 and is expected to grow at a significant rate during the forecast period. This is attributed to high prevalence of cancer, rising healthcare expenditure and approval of new drug formulations in the region. Asia Pacific is expected to be the fastest growing region owing to increasing patient pool, rising awareness for treatment and improving healthcare infrastructure.
Key players operating in the cancer chemotherapy associated nausea and vomiting therapeutics market are Johnson & Johnson Services, Inc., Teleflex Incorporated, Cooper Surgical, Inc., Genicon, Medtronic, B. Braun SE, Applied Medical Resources Corporation, LaproSurge, Purple Surgical, CONMED, Hangzhou Boer Medical Instruments Co., Ltd., Duomed, Changzhou Cheayoo Medical Devices Co., Ltd., and Tianjin Zhichao Medical Technology Co., Ltd.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
